Project Grant R21DA061428

Award Date 6/15/25
Completion Date 5/31/27
Dollars Obligated $233K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $789,677 to the Research Triangle Institute (RTI International) to conduct a community-based, longitudinal, mixed-methods study investigating the growing crisis of xylazine exposure among people who use drugs (PWUD) in the Southeastern U.S. The key products and services to be delivered through this funding include: 1) employing...
This Project Grant award for $423,708 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support research to investigate the effects of fentanyl-xylazine drug mixtures on cardiorespiratory function and subjective effects in rats. Specifically, the research aims to characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure, temperature, and respiration, as well as determine if...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $277,389 to Synventa LLC to conduct preclinical studies to confirm the ability of the drug Etimizol to reverse respiratory depression induced by the combination of the opioid fentanyl and the animal sedative xylazine. The key objectives are to: 1) characterize xylazine's ability to cause respiratory depression alone and in combination with fentanyl...
This $1,481,760 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate how methamphetamine (MA) exposure leads to inflammasome activation and altered immunity in people living with HIV (PWH) on antiretroviral therapy (ART). The key products and services to be delivered through this 5-year project include: 1) determining how MA exposure induces inflammasome activation and inflammation in PWH on...
The U.S. National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $688,271 Project Grant to Yale University to conduct a study examining spatial and temporal variability in a state's illicit drug market. The key objectives of this 5-year project are to: (1) expand street-based testing of drug samples from representative samples of people who use drugs, (2) develop a robust wastewater sampling and testing system to determine...
This Project Grant award of $234,000.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to understand the impact of opioids on HIV transcription and latency. The research will utilize a novel dual fluorescent and bioluminescent HIV virus to visualize and measure the effects of opioids like fentanyl, morphine, and methadone on HIV proviral transcription in microglia and astrocytes. The goal is to identify key...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,563,642 to conduct a randomized, directly observed therapy (DOT) study to examine the pharmacology and adherence patterns of doxycycline post-exposure prophylaxis (PEP) against sexually transmitted infections (STIs) among men who have sex with men, transgender women, and cisgender women. The goal is to...
This $4.68 million project grant from the National Institute on Drug Abuse, part of the Department of Health and Human Services, will fund research under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The University of Michigan will conduct a prospective cohort study of 400 adults with opioid-involved polysubstance use in Michigan. Researchers will collect detailed weekly data on participants' substance use patterns and motivations over four weeks to understand nuanced profiles...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $804,728 in funding to the Regents of the University of California at Riverside to investigate the role of methamphetamine and cysteinyl leukotrienes in HIV persistence. The key objectives are to: 1) Determine how methamphetamine engages the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis to escalate...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $721,217 to The Trustees of the University of Pennsylvania to increase naloxone availability and use in public libraries, a high-risk setting for opioid overdoses. The overarching goal is to advance evidence on place-based naloxone implementation and overdose reversal readiness in libraries, which have experienced over 1 in 10 on-site overdoses...

EVALUATION OF THE PREVALENCE OF XYLAZINE AND ETIOLOGY OF XYLAZINE RELATED INVASIVE INFECTIONS - ABSTRACT / PROJECT SUMMARY XYLAZINE IS AN ALPHA 2 ADRENERGIC RECEPTOR AGONIST WITH SEDATIVE AND ANALGESIC PROPERTIES WHICH IS INCREASINGLY BEING FOUND IN THE US ILLEGAL DRUG SUPPLY AND LINKED TO NUMEROUS ADVERSE HEALTH OUTCOMES INCLUDING OVERDOSE DEATHS, SKIN ULCERATIONS AND INFECTIONS. PUBLIC HEALTH EFFORTS ARE LIMITED BY A LACK OF DATA ON THE TYPE OF ILLICIT CONTROLLED SUBSTANCES THAT HAVE BEEN ADULTERATED BY XYLAZINE, WHILE AT THE SAME TIME CLINICIANS FACE AN INCREASING NUMBER OF PATIENTS PRESENTING WITH LARGE PAINFUL SKIN ULCERATIONS, MANY OF WHICH ARE COMPLICATED BY NECROTIZING INFECTIONS OR UNDERLYING OSTEOMYELITIS. HOWEVER, IT IS UNCLEAR TO WHAT DEGREE THESE XYLAZINE RELATED COMPLICATIONS ARE THE RESULT OF INFECTIONS DUE TO PATHOGENS DIRECTLY INJECTED FROM A CONTAMINATED DRUG SUPPLY, COMPARED WITH SECONDARY SUPERINFECTIONS FROM SKIN COLONIZING MICROBES OF VASOCONSTRICTION MEDIATED CHEMICAL INJURIES. OUR PROPOSED GRANT APPLICATION SEEKS TO FILL THIS CRITICAL GAP IN THE LITERATURE. IN AIM 1 WE WILL CONDUCT ACTIVE SURVEILLANCE OF THE LOCAL ILLICIT DRUG SUPPLY IN ST. LOUIS MISSOURI USING MASS SPECTROMETRY AND MICROBIOLOGIC CULTURES OF SYRINGE RESIDUE. THIS WILL ALLOW US TO IDENTIFY THE FULL SPECTRUM OF ILLICIT DRUGS ASSOCIATED WITH XYLAZINE WHILE ALSO PERFORMING ONGOING SURVEILLANCE FOR THE POTENTIAL EMERGENCE OF ANY OTHER NOVEL ADULTERANTS. MICROBIOLOGIC ANALYSES OF SYRINGE RESIDUE WILL ALLOW US TO DETERMINE IF XYLAZINE CONTAMINATED ILLICIT DRUGS SUPPORT INCREASED LEVELS OF BACTERIAL CONTAMINATION COMPARED TO OTHER ILLICIT DRUGS WHICH MIGHT EXPLAIN THE HIGH DEGREE OF INVASIVE INFECTIONS ASSOCIATED WITH THIS NOVEL ADULTERANT. AIM 2 WILL CONSENT HOSPITALIZED PATIENTS WITH XYLAZINE RELATED INVASIVE INFECTIONS AND COMPARE BACTERIAL PATHOGENS ISOLATED FROM CLINICAL SPECIMENS WITH SKIN COLONIZING MICROFLORA AND BACTERIAL AND FUNGAL SPECIES ISOLATED FROM XYLAZINE CONTAINING SYRINGE RESIDUE COLLECTED IN AIM 1. BY COMPARING CORE GENOME SINGLE NUCLEOTIDE POLYMORPHISM (CGSNP) DISTANCES WE WILL DETERMINE IF CLINICAL SITES OF INFECTION ARE THE RESULT OF BACTERIAL SUPERINFECTION FROM SKIN COLONIZING ORGANISMS OR AROSE DIRECTLY FROM BACTERIAL SPECIES INNOCULATED ALONG WITH XYLAZINE CONTAINING ILLICIT DRUGS. THE WORK PROPOSED IN THIS APPLICATION HAS THE POTENTIAL TO DIRECTLY IMPACT PUBLIC HEALTH AND PATIENT CARE. A CLEAR UNDERSTANDING OF WHAT PATHOGENS PEOPLE WHO USE XYLAZINE ARE ROUTINELY EXPOSED TO, AND AN INCREASED UNDERSTANDING OF THE ETIOLOGY OF XYLAZINE RELATED INFECTIOUS COMPLICATIONS IS URGENTLY NEEDED TO GUIDE PUBLIC HEALTH POLICY AND TARGET HARM REDUCTION INTERVENTIONS.

Posted 6/6/25, 12:00 AM